To the Editor.—
The recent letter by Peter L. Sosnow, MD (1982;247:1275), on the potential clinical utility of a 5-aminosalicylic acid (5-ASA) drug for inflammatory bowel disease is timely and well taken. There is indeed convincing evidence to indicate that 5-ASA is the active moiety in the sulfasalazine (Azulfidine) molecule. Scientists at Pharmacia Laboratories have been most active in initiating and supporting such research and in the search for a clinically useful 5-ASA analogue. In that regard, I would like to mention sodium diazosalicylate (CJ-91B),1 which is currently under clinical investigation. Sodium diazosalicylate consists only of two 5-ASA entities coupled by an azo bond. Given orally, it passes essentially intact to the colon, where the azo bond is opened by bacterial action in much the same way that the sulfasalazine azo bond is split.2 However, the 5-ASA thus liberated from sodium diazosalicylate is free of carrier materials such
Gabel LP. Sodium Diazosalicylate. JAMA. 1982;248(8):924. doi:10.1001/jama.1982.03330080014013
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: